MIFCOR, Inc.

Currently, there is no available drug that reduces tissue death during heart attack, one of the leading causes of death worldwide. MIFCOR is addressing this great need by developing a first-in-class biologic therapeutic for protecting tissue from cell death following reduced blood flow (ischemia). Our therapeutic, MIF-2, takes advantage of breakthrough science: by targeting a novel biological pathway, it protects tissue from ischemia-induced death. We have made concrete steps toward commercialization of this revolutionary therapy, including successfully executing an exclusive option on an IP portfolio, building a business plan, assembling a team of world-class advisors, and getting interest from potential investors.